Cidofovir nucleotide analog topical gel data

Results from a Phase I/II randomized, double-blind, placebo-controlled trial with cidofovir topical gel showed a statistically significant treatment effect in 30 AIDS patients with refractory herpes simplex virus (HSV) lesions.

Subjects were given placebo (n=10), or 0.3 (n=11) or 1 percent (n=9) doses once daily for five days, after which patients were observed for 15 days. The study's primary end point was the rate of complete or partial (>50 percent) healing. ...